QV Bioelectronics has been spotlighted in the National Institute for Health and Care Research (NIHR) 2025/26 Annual Report, recognised in the Investment chapter for the role NIHR funding played in the development of GRACE, our world-first implantable electric field therapy device for brain cancer.
Glioblastoma affects around 2,200 adults in the UK each year, with only 3% of patients surviving five years after diagnosis and very limited treatment options available. With early-stage NIHR funding, we developed a fully implantable device that uses electric fields to target cancer cells remaining in the brain after surgery. Since that initial support, QV Bioelectronics has secured £4.5 million in private investment to progress towards first-in-human studies.
Co-founder Dr Christopher Bullock said: "Our mission is to develop technology that can meaningfully extend life and give people more time with those they love. This investment allows us to take a major step towards that goal, progressing into first-in-human studies and generating the vital evidence needed to bring a new treatment approach to the patients who need it most."
Being recognised alongside organisations such as Moderna, GSK, and Autolus Therapeutics reflects the calibre of innovation the NIHR is enabling across the UK, and we're proud to be part of that story.
Read the full NIHR 2025/26 Annual Report here.